Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Leukemia & Lymphoma|December 30, 2020
The propriety of upgrading responses to venetoclax + azacitidine in newly diagnosed patients with acute myeloid leukemiaDiana Abbott, Evan Cherry, Maria Amaya, et al.
Leukemia & Lymphoma|May 30, 2024
White blood cell count nadir to zero following intensive chemotherapy as a predictive factor for patients with acute myeloid leukemiaJacob Fang, Grace Bosma, Dara Aisner, et al.
Leukemia & Lymphoma|September 7, 2018
Clinicopathologic and genetic spectrum of infantile B-lymphoblastic leukemia: a multi-institutional studyVirginia Knez, Xin Liu, Jeffrey Schowinsky, et al.
Leukemia & Lymphoma|September 22, 2015
Clonality of neutrophilia associated with plasma cell neoplasms: report of a SETBP1 mutation and analysis of a single institution seriesBrett Stevens, Julia Maxson, Jeffrey Tyner, et al.
Blood Advances|October 5, 2021
Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemiaEvan M Cherry, Diana Abbott, Maria Amaya, et al.
Eclinicalmedicine|October 27, 2025
Omacetaxine and azacitidine for untreated patients with myelodysplastic syndromes and excess blasts: a phase I/II clinical trialDaniel A Pollyea, Brett M Stevens, Diana Abbott, et al.
Haematologica|April 13, 2023
Higher-dose venetoclax with measurable residual disease-guided azacitidine discontinuation in newly diagnosed acute myeloid leukemiaJonathan A Gutman, Amanda Winters, Andrew Kent, et al.
Cancer Discovery|June 26, 2023
A Novel Type of Monocytic Leukemia Stem Cell Revealed by the Clinical Use of Venetoclax-Based TherapyShanshan Pei, Ian T Shelton, Austin E Gillen, et al.
Haematologica|February 26, 2026
Venetoclax and azacitidine for younger acute myeloid leukemia patients independent of fitness for intensive chemotherapyJustin Watts, Ellen Madarang, Diana Abbott, et al.
Cancer Discovery|January 25, 2020
Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid LeukemiaShanshan Pei, Daniel A Pollyea, Annika Gustafson, et al.
Pageof 2